drugset / Trial / NCT06021197
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
Phase 2
Recruiting
90 enrolled
China Medical University Hospital
National Science and Technology Council, Taiwan · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Cognitive impairment, the core psychopathology of schizophrenia, usually persists in schizophrenia patients even during symptomatic remission. While cognitive impairment associated with schizophrenia (CIAS) is an important therapeutic target, hypofunction of N-methyl-D-aspartate receptor (NMDAR) is a key factor of CIAS. This study aims to examine the efficacy and safety of an NMDA-enhancer (NMDAE) for the treatment of CIAS in schizophrenia patients during symptomatic remission.
Timeline
- Start
- 2023-10-12
- Primary completion
- 2027-12
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NMDAE | Unknown | — | — |